Welcome to our dedicated page for Clearmind Medici SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clearmind Medicine Inc.'s SEC filings document foreign private issuer reports for a clinical-stage biotech developing non-hallucinogenic, neuroplastogen-derived psychedelic therapeutics. Form 6-K reports furnish press releases on CMND-100, MEAI-based Alcohol Use Disorder clinical development, European patent activity for PTSD compounds, and communications tied to FDA regulatory pathways.
The filings also record capital-structure matters, including securities purchase agreements, convertible promissory notes, conversions into common shares and amendments to financing capacity. Governance disclosures cover board composition, committee assignments and Nasdaq independence determinations, while incorporated registration statements on Form F-3 and Form S-8 connect current reports to the company's securities registration record.
Clearmind Medicine Inc. reported unaudited results for the three months ended January 31, 2026, showing a net loss of $3.85 million with no revenue, compared with a $1.07 million loss a year earlier. Operating expenses rose to $3.66 million, mainly from higher general and administrative and research and development costs.
Cash and cash equivalents increased to $9.26 million and working capital to $8.12 million, driven by equity issuances, warrant exercises and conversion of convertible loans into shares, which reduced total liabilities to $2.91 million. The company is funding phase I/IIa trials of its CMND‑100 psychedelic treatment for Alcohol Use Disorder, where an independent safety board approved continuation after a positive interim safety review.
Management notes negative operating cash flows of $2.08 million, an accumulated deficit of $31.73 million, and dependence on additional financing, stating that these conditions raise substantial doubt about Clearmind’s ability to continue as a going concern, even though the financial statements are prepared on a going-concern basis.
Clearmind Medicine Inc. is advancing its CMND-100 program for Alcohol Use Disorder by continuing enrollment for the third cohort of its ongoing FDA-approved Phase I/IIa clinical trial. This step follows positive topline results from the second cohort, which showed continued safety and tolerability.
The company’s Data and Safety Monitoring Board unanimously approved proceeding, allowing recruitment at leading centers including Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center. CMND-100 is a proprietary, non-hallucinogenic, MEAI-based oral candidate designed to treat moderate to severe Alcohol Use Disorder without requiring adjunct psychotherapy.
Clearmind Medicine Inc. filed a Form 6-K to furnish a press release announcing the publication of an international patent application under the Patent Cooperation Treaty for a novel combination therapy targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD).
The therapy combines Clearmind’s proprietary compound 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) from its collaborator NeuroThera Labs Inc. The patent publication describes the potential for a non-hallucinogenic neuroplastogen approach to address obesity and MASLD, conditions affecting large portions of the global adult population.
Clearmind notes that this therapeutic option may offer a safer, easier and more cost effective alternative compared with GLP-1 agonists, in a weight loss drugs market valued at approximately $37 billion in 2025 and forecasted to reach $226 billion by 2035. The company highlights its broader intellectual property portfolio of nineteen patent families, including 31 granted patents.
Clearmind Medicine Inc amendment reports that Nissim Daniel filed a Schedule 13G/A stating beneficial ownership in the issuer's common shares. The filing identifies the reporting person, citizenship (Israel), an address in Ramat Gan, and CUSIP 185053402, and states ownership of 5 percent or less of a class.
Clearmind Medicine Inc. reported that an independent Data and Safety Monitoring Board has completed a second interim review of its ongoing FDA-approved Phase I/IIa trial of CMND-100 for alcohol use disorder and recommended the study continue. Additional top-line safety data from a second cohort, where the dose was doubled versus the first cohort, showed no serious adverse events and good overall tolerability. On this basis, the company is advancing to a third cohort with an 80 mg dose per administration. The multinational trial evaluates safety, tolerability, pharmacokinetics and preliminary efficacy in patients with moderate to severe alcohol use disorder at leading sites including Johns Hopkins University and major Israeli medical centers.
Clearmind Medicine Inc. is reducing the second tranche of its previously announced convertible promissory note financing from an aggregate principal amount of $1,900,000 to $600,000, with a cash purchase price equal to 90% of principal, or $540,000. The first tranche for $600,000 in principal, generating $540,000 in cash proceeds, closed on February 4, 2026. These tranches form part of a broader facility of up to $10,000,000 in convertible promissory notes with CLA Investors. The company states that the reduction reflects its current capital requirements and liquidity position, while all other terms of the second-tranche notes remain unchanged.
Clearmind Medicine Inc. received an amended Schedule 13G from Iroquois Capital Management, Richard Abbe and Kimberly Page reporting beneficial ownership through warrants. The filing states that Iroquois Capital Management and Kimberly Page each beneficially own 131,886 shares of common stock issuable upon exercise of warrants, representing 8.1% of the class. Richard Abbe is reported as beneficially owning 166,464 shares issuable upon exercise of warrants, representing 9.99% of the common stock. These amounts reflect warrant terms that block exercises above 9.99% ownership, or 4.99% for certain warrants. The percentages are based on 1,499,838 common shares outstanding as of January 19, 2026, and the filers certify the securities are not held for the purpose of changing or influencing control of Clearmind.
Clearmind Medicine Inc. reports updates to its previously announced convertible loan arrangement with institutional investors. The company has issued and sold additional convertible promissory notes with an aggregate principal amount of $2,500,000, for cash proceeds equal to 90% of principal, or $2,250,000. The total facility under the securities purchase agreements allows issuance of up to $10,000,000 in such notes over time.
On February 9, 2026, Clearmind and the investors entered into a conversion agreement under which each investor converted $300,000 of principal into common shares at an agreed conversion price of $1.25 per share. They also amended the floor price in the form of promissory note attached to the purchase agreements to $1.25 per common share, aligning the minimum conversion level with the negotiated conversion price.
Clearmind Medicine Inc. reports additional positive safety topline results from the second cohort of its ongoing FDA-approved Phase I/IIa trial of CMND-100, an oral, non-hallucinogenic MEAI-based drug candidate for treating alcohol use disorder. Another six patients completed treatment with no serious adverse events and overall good tolerability, reinforcing the favorable safety profile seen in the first cohort.
The multinational study evaluates safety, tolerability, pharmacokinetics and preliminary efficacy in patients with moderate to severe alcohol use disorder at sites including Johns Hopkins University and leading Israeli medical centers. Clearmind is a clinical-stage psychedelic pharmaceutical biotech with nineteen patent families and 31 granted patents focused on underserved conditions such as alcohol use disorder.
Clearmind Medicine Inc. has entered a development agreement with Polyrizon Ltd. to create an intranasal formulation of its proprietary, non-hallucinogenic neuroplastogen MEAI. The goal is to enhance drug delivery and support ongoing and future clinical programs targeting addiction-related and other central nervous system disorders.
The collaboration combines Clearmind’s neuroplastogen expertise with Polyrizon’s intranasal hydrogel technology to potentially improve bioavailability, therapeutic effect and patient experience. Polyrizon is a related party under Canadian securities rules, and Clearmind is relying on available exemptions from formal valuation and minority shareholder approval for this related party transaction.